# A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies

> **NCT04954456** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** QLS31901

## Key facts

- **NCT ID:** NCT04954456
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-02
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954456, "A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04954456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*